Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-smal-cell lung cancer

Annals of Oncology

Volumn 15, Issue 1, 2004, Pages 33-37

  Santoro, Armando ^a   Cavina, R ^a   Latteri, F ^a   Zucali, P A ^a   Ginanni, V ^a   Campagnoli, E ^a   Ferrari, B ^a   Morenghi, E ^a   Pedicini, V ^a   Roncalli, M ^b   Alloisio, M ^a   Ravasi, G ^a   Soto Parra, H J ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Epidermal growth factor receptor; Gefitinib; Non small cell lung cancer

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG ERUPTION; DRUG TOLERABILITY; FEMALE; HEMATOLOGICAL PARAMETERS; HEPATOBILIARY PARAMETERS; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; INFORMED CONSENT; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL SYSTEM PARAMETERS; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 9144244180     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh010     Document Type: Article

References (29)

1. Cross M, Dexter TM. Growth factors in development, transformation, and tumorigenesis. Cell 1991; 64: 271-280.
2. Wells A. The epidermal growth factor receptor (EGFR): a new target in cancer therapy. Signal 2000; 1: 4-11.
3. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997; 17: 1595-1606.
4. Albanell J, Rojo F, Averbuch S et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20: 110-124.
5. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61: 203-212.
6. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasm. J Clin Oncol 2001; 9: 32S-40S.
7. Yamamoto T, Ikawa S, Akiyama T et al. Similarity of protein encoded by human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986; 319: 230-234.
8. Moscatello DK, Holgado-Madruga M, Godwin AK et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995; 5: 5536-5539.
9. Rusch V, Baselga J, Cordon-Cardo C et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53: 2379-2385.
10. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241-250.
11. Salomon DS, Brandt R, Ciardiello F et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
12. Baselga J. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes. J Clin Oncol 2002; 20: 2217-2219.
13. Ciardiello F, Caputo R, Bianco R et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6: 2053-2063.
14. Herbst RS, Maddox AM, Rothenberg ML et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 15: 3815-3825.
15. Ranson M, Hammond LA, Ferry D et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20: 2240-2250.
16. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 15: 2237-2246.
17. Kris MG, Natale RB, Herbst RS et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer patients who had failed platinum-and docetaxel-based regimens (IDEAL 2). Proc Am Soc Clin Oncol 2002; 21: 292a (Abstr 1166).
18. Response evaluation criteria in solid tumors (RECIST) quick reference. http://www.nci.nih.gov/bip/RECIST.htm
19. Fossella FV, Lee JS, Hong WK. Management strategies for recurrent non-small cell lung cancer. Semin Oncol 1997; 24: 455-462.
20. Fossella F, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18: 2354-2362.
21. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095-2103.
22. Carney DN. Lung cancer: time to move on from chemotherapy. N Engl J Med 2002; 346: 126-128.
23. Bunn PA, Franklin W. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin Oncol 2002; 29: 38-44.
24. Ruckdeschel JC, Simon G, Antonia S et al. ZD1839 ('Iressa') as a single agent for the treatment of metastatic non-small-cell lung cancer. Proc Am Soc Clin Oncol 2002; 21: 318a (Abstr 1269).
25. Liem AK, Cheng H, Quan E et al. Expanded access single institution clinical program experience with ZD1839 (Iressa ™) for patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002; 21: 222b (Abstr 2705).
26. Janne PA, Ostler PA, Lucca J et al. ZD1839 ('Iressa') shows antitumor activity in patients with recurrent non-small cell lung cancer treated on a compassionate use protocol. Proc Am Soc Clin Oncol 2002; 21: 319a (Abstr 1274).
27. Giaccone G, Johnson DH, Manegold C et al. A phase III clinical trial of ZD1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol 2002; 13 (Suppl 5): 2 (Abstr 40).
28. Johnson DH, Herbst R, Giaccone G et al. ZD1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced no-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol 2002; 13 (Suppl 5): 127 (Abstr 4680).
29. Yarden Y, Sliwkowski M. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.